Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Patient Death Halts Capsida's Gene Therapy Trial for Rare Epilepsy Disorder

Patient Death Halts Capsida's Gene Therapy Trial for Rare Epilepsy Disorder

Capsida Biotherapeutics has suspended a clinical trial of its experimental gene therapy CAP-002 following the death of the first patient treated in the study. The therapy, designed to address STXBP1-related epileptic encephalopathy disorders, was in early-stage testing when the incident occurred.

NoahAI News9/12/2025
AbbVie Secures Extended Exclusivity for Rinvoq, Bolstering Immunology Portfolio

AbbVie Secures Extended Exclusivity for Rinvoq, Bolstering Immunology Portfolio

AbbVie has successfully negotiated settlements with multiple generic manufacturers, effectively extending the market exclusivity of its blockbuster immunology drug Rinvoq (upadacitinib) in the United States until April 2037. This strategic move aims to protect the company's growing immunology franchise in the wake of Humira's patent expiration.

NoahAI News9/12/2025
Avidity's DMD Therapy Shows Promise, Paving Way for FDA Submission

Avidity's DMD Therapy Shows Promise, Paving Way for FDA Submission

Avidity Biosciences has reported encouraging results from two mid-stage trials of its investigational exon-44-skipping therapy for Duchenne muscular dystrophy (DMD), potentially clearing the path for a biologics license application (BLA) to the FDA. The therapy, delpacibart zotadirsen (del-zota), demonstrated significant functional improvements in patients after one year of treatment, reversing disease progression in key metrics.

NoahAI News9/12/2025
Merck Pulls Out of UK R&D Operations, Citing Undervaluation of Innovation

Merck Pulls Out of UK R&D Operations, Citing Undervaluation of Innovation

Pharmaceutical giant Merck has announced a significant restructuring of its research and development operations, including a complete withdrawal from the United Kingdom. The move, part of a broader cost-cutting initiative, will result in the closure of multiple facilities and the loss of hundreds of jobs.

NoahAI News9/12/2025
Masimo and Philips Extend Strategic Collaboration in Patient Monitoring Technologies

Masimo and Philips Extend Strategic Collaboration in Patient Monitoring Technologies

Masimo and Philips have announced a renewal of their multi-year strategic collaboration, focusing on the integration of patient monitoring technologies and the development of new tools, including artificial intelligence algorithms. This partnership extension comes as a significant development in the medical device industry, particularly in the realm of patient monitoring systems.

NoahAI News9/12/2025
FDA's Top Doctor Reclaims Dual Role Amid Controversy and Agency Reshuffling

FDA's Top Doctor Reclaims Dual Role Amid Controversy and Agency Reshuffling

In a surprising turn of events, Dr. Vinay Prasad has been reappointed as the Food and Drug Administration's chief medical and scientific officer, just six weeks after his dramatic departure from the agency. This development comes on the heels of Prasad's recent return to lead the FDA's biologics medicine division, signaling a rapid series of changes in the agency's leadership structure.

NoahAI News9/12/2025
Exact Sciences Launches Groundbreaking Multi-Cancer Blood Test, Cancerguard

Exact Sciences Launches Groundbreaking Multi-Cancer Blood Test, Cancerguard

Exact Sciences has unveiled its highly anticipated Cancerguard blood test, designed to detect early stages of multiple cancer types. This launch marks a significant milestone in the company's mission to revolutionize cancer screening and early detection.

NoahAI News9/12/2025
Kaiser Permanente Expands into Nevada through Joint Venture with Renown Health

Kaiser Permanente Expands into Nevada through Joint Venture with Renown Health

Kaiser Permanente, the nation's largest nonprofit health system, has announced a significant expansion into northern Nevada through a joint venture with Renown Health. The partnership, set to launch in early 2026, will establish a new entity called Kaiser Permanente Nevada, combining Kaiser's national expertise with Renown's local presence.

NoahAI News9/12/2025
Patent Dispute Erupts Between Arrowhead and Ionis Over RNAi Candidate for Rare Metabolic Disease

Patent Dispute Erupts Between Arrowhead and Ionis Over RNAi Candidate for Rare Metabolic Disease

Arrowhead Pharmaceuticals has initiated legal action against Ionis Pharmaceuticals, challenging the latter's patent claims related to a potential rival treatment for familial chylomicronemia syndrome (FCS). The lawsuit, filed in the U.S. District Court for the District of Delaware, seeks to invalidate Ionis' patent assertions regarding Arrowhead's investigational drug plozasiran.

NoahAI News9/12/2025
GE HealthCare Acquires Icometrix, Bolstering Brain Imaging Capabilities for Alzheimer's Treatment

GE HealthCare Acquires Icometrix, Bolstering Brain Imaging Capabilities for Alzheimer's Treatment

GE HealthCare has announced its acquisition of Icometrix, a Belgian brain analysis software company, in a strategic move to enhance its neurological imaging portfolio. The deal, disclosed on Wednesday for an undisclosed sum, centers on Icometrix's AI-powered brain imaging software, with a particular focus on tools for monitoring side effects of new Alzheimer's disease treatments.

NoahAI News9/12/2025
Merck's Capvaxive Shows Promise in Children, Expanding Beyond Senior Market

Merck's Capvaxive Shows Promise in Children, Expanding Beyond Senior Market

Merck's pneumococcal vaccine Capvaxive, originally designed for seniors, has demonstrated potential efficacy in children and adolescents, according to recent phase 3 trial results. This development could significantly expand the vaccine's market reach and impact on public health.

NoahAI News9/12/2025
Intercept's Ocaliva Withdrawn from US Market Amid Regulatory Challenges

Intercept's Ocaliva Withdrawn from US Market Amid Regulatory Challenges

Intercept Pharmaceuticals has announced the withdrawal of its liver disease drug Ocaliva (obeticholic acid) from the US market following a request from the Food and Drug Administration (FDA). This development marks the latest in a series of setbacks for the company and its flagship product.

NoahAI News9/12/2025
«1...345...67»